{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:59:57Z","timestamp":1764061197220,"version":"3.40.5"},"reference-count":231,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.pathol.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T04:16:21Z","timestamp":1702959381000},"page":"239-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictive and prognostic molecular biomarkers in lymphomas"],"prefix":"10.1016","volume":"56","author":[{"given":"J. Bryan","family":"Iorgulescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.12.001_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/095952873201700106","article-title":"On some morbid appearances of the absorbent glands and spleen","volume":"17","author":"Hodgkin","year":"1832","journal-title":"Med Chir Trans"},{"key":"10.1016\/j.pathol.2023.12.001_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3181\/00379727-47-13084P","article-title":"Immunological properties of an antibody containing a fluorescent group","volume":"47","author":"Coons","year":"1941","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1601-5223.1956.tb03010.x","article-title":"The chromosome number of man","volume":"42","author":"Tjio","year":"1956","journal-title":"Hereditas"},{"key":"10.1016\/j.pathol.2023.12.001_bib4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1073\/pnas.64.2.600","article-title":"Molecular hybridization of radioactive DNA to the DNA of cytological preparations","volume":"64","author":"Pardue","year":"1969","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2023.12.001_bib5","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1126\/science.150.3698.910","article-title":"Electronic separation of biological cells by volume","volume":"150","author":"Fulwyler","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.pathol.2023.12.001_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.150.3696.630","article-title":"Spectrophotometer: new instrument for ultrarapid cell analysis","volume":"150","author":"Kamentsky","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.pathol.2023.12.001_bib7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1126\/science.163.3872.1213","article-title":"Cell microfluorometry: a method for rapid fluorescence measurement","volume":"163","author":"Van Dilla","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.pathol.2023.12.001_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (Aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"N\u00a0Engl J Med"},{"year":"2022","series-title":"Classification of Hematolymphoid Tumours","key":"10.1016\/j.pathol.2023.12.001_bib9"},{"key":"10.1016\/j.pathol.2023.12.001_bib10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia","key":"10.1016\/j.pathol.2023.12.001_bib12"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for Pediatric Acute Lymphoblastic Leukemia","key":"10.1016\/j.pathol.2023.12.001_bib13"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","key":"10.1016\/j.pathol.2023.12.001_bib14"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for B-Cell Lymphomas","key":"10.1016\/j.pathol.2023.12.001_bib15"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for Waldenstr\u00f6m Macroglobulinemia\/ Lymphoplasmacytic Lymphoma","key":"10.1016\/j.pathol.2023.12.001_bib16"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for Hairy Cell Leukemia","key":"10.1016\/j.pathol.2023.12.001_bib17"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for T-Cell Lymphomas","key":"10.1016\/j.pathol.2023.12.001_bib18"},{"year":"2023","series-title":"NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma","key":"10.1016\/j.pathol.2023.12.001_bib19"},{"key":"10.1016\/j.pathol.2023.12.001_bib20","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pathol.2023.12.001_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/ng.3301","article-title":"The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia","volume":"47","author":"Paulsson","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib23","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/JCO.20.02370","article-title":"Favorable trisomies and ETV6-RUNX1 predict cure in low-risk B-cell acute lymphoblastic leukemia: results from children\u2019s oncology group trial AALL0331","volume":"39","author":"Mattano","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib26","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2013.48.9377","article-title":"Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97\/99 and UKALL2003 trials","volume":"31","author":"Moorman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejmg.2016.01.006","article-title":"Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukemia","volume":"59","author":"Harrison","year":"2016","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature13115","article-title":"Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukemia","volume":"508","author":"Li","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib33","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib34","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib35","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"van der Veer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib36","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2023.12.001_bib38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2018-99-110221","article-title":"A\u00a0phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): dose-finding results from the part 1 safety phase","volume":"132","author":"Tasian","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2023.12.001_bib39","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/blood-2022-164699","volume":"140","author":"Tasian","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib40","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/gcc.20613","article-title":"The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1","volume":"47","author":"Parker","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib42","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2023.12.001_bib43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood-2021-144843","article-title":"A\u00a0phase 2 study to test the feasibility, safety and efficacy of the addition of blinatumomab to the Interfant06 backbone in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia. A collaborative study of the Interfant Network","volume":"138","author":"Van Der Sluis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib44","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","article-title":"Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2023.12.001_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-137376","article-title":"Pediatric patients with relapsed\/refractory acute lymphoblastic leukemia harboring heterogeneous genomic profiles respond to venetoclax in combination with chemotherapy","volume":"136","author":"Place","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib46","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.2019000813","article-title":"IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?","volume":"135","author":"Stanulla","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17474086.2020.1685866","article-title":"Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia","volume":"13","author":"Bloom","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2006.06337.x","article-title":"Down syndrome and acute lymphoblastic leukemia","volume":"135","author":"Whitlock","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib50","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib51","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pathol.2023.12.001_bib52","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib53","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2010.025338","article-title":"Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation","volume":"95","author":"Oscier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib54","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib55","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib56","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib57","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Oscier","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib58","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Kr\u00f6ber","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08440.x","article-title":"B-cell receptor, clinical course and prognosis in chronic lymphocytic leukemia: the growing saga of the IGHV3 subgroup gene usage","volume":"153","author":"Dal-Bo","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib61","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib62","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.12.001_bib63","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib64","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3324\/haematol.2019.229161","article-title":"Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1","volume":"105","author":"Tausch","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib65","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.23993","article-title":"Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib66","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib67","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2023.12.001_bib68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hon.3163_116","article-title":"Genomic evolution and resistance to pirtobrutinib in covalent Btk-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I\/Ii Bruin Study","volume":"41","author":"Patel","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib69","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2023.12.001_bib70","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib71","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/sj.leu.2404856","article-title":"Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma","volume":"21","author":"Iqbal","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib72","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","article-title":"Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact","volume":"129","author":"Ennishi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib73","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2023.12.001_bib75","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib76","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib77","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib78","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2023.12.001_bib79","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cll.2022.04.005","article-title":"Molecular diagnostic testing for hematopoietic neoplasms: linking pathogenic drivers to personalized diagnosis","volume":"42","author":"Hergott","year":"2022","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib80","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.26068","article-title":"First-line treatment of double-hit and triple-hit lymphomas: survival and tolerance data from a retrospective multicenter French study","volume":"96","author":"Laude","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib81","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib82","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib84","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood.2019002699","article-title":"Distinct molecular profile of IRF4-rearranged large B-cell lymphoma","volume":"135","author":"Ramis-Zaldivar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib85","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2013-04-495804","article-title":"A\u00a0capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma","volume":"122","author":"Bouamar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib86","series-title":"Atlas of Lymph Node Pathology","first-page":"251","article-title":"ALK-positive large B-cell lymphoma","author":"Miranda","year":"2013"},{"key":"10.1016\/j.pathol.2023.12.001_bib87","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/modpathol.2013.73","article-title":"ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements","volume":"26","author":"Valera","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib88","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015443","article-title":"Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib89","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib90","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.2020008194","article-title":"BCL-2 inhibition in follicular lymphoma: can we tip the scales?","volume":"136","author":"Fowler","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib91","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.2022018719","article-title":"Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns","volume":"142","author":"Dreval","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib92","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib93","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib94","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.17550","article-title":"Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies","volume":"194","author":"Bussot","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib95","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O\u2019Shea","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib96","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib97","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2002-08-2482","article-title":"BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma","volume":"102","author":"Akasaka","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib98","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","article-title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization","volume":"154","author":"Li","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib99","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib100","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.001_bib101","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3324\/haematol.12330","article-title":"Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations","volume":"93","author":"Sander","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib102","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib103","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biological and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2023.12.001_bib104","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib105","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib106","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib107","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib108","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/sj.leu.2403501","article-title":"Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites","volume":"18","author":"Streubel","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib109","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pathol.2023.12.001_bib110","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2018.191601","article-title":"Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites","volume":"103","author":"Moody","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.4933","article-title":"Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma","volume":"243","author":"Moody","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib112","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib113","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2017-01-765107","article-title":"Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemia","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib115","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib116","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib117","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.001_bib118","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib119","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib120","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2021005304","article-title":"Adoptive T-cell therapy for Hodgkin lymphoma","volume":"5","author":"Ho","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.001_bib121","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00673-x","article-title":"Structural variants shape the genomic landscape and clinical outcome of multiple myeloma","volume":"12","author":"Ashby","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2023.12.001_bib123","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib124","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A\u00a0compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A\u00a0high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib126","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib127","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib128","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group Consensus Statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pathol.2022.12.350","article-title":"An update on genetic aberrations in T-cell neoplasms","volume":"55","author":"Parilla","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2023.12.001_bib131","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib132","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1096-9896(199907)188:3<267::AID-PATH357>3.0.CO;2-N","article-title":"Gene rearrangements in T-cell lymphoblastic lymphoma","volume":"188","author":"Pilozzi","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib133","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib134","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2020005381","article-title":"Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance","volume":"137","author":"Khanam","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2023.12.001_bib136","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1182\/blood-2012-11-465138","article-title":"Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations","volume":"121","author":"Neumann","year":"2013","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2023.12.001_bib137","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood-2018-99-110388","article-title":"Interim results from Fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid\/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor 1 (FGFR1)","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib138","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/gcc.22821","article-title":"Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia","volume":"59","author":"Patil","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib139","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood.2019003348","article-title":"Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling","volume":"136","author":"Oberbeck","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib140","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib141","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ajh.24679","article-title":"Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia","volume":"92","author":"Hu","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib142","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.22313","article-title":"Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker","volume":"55","author":"Stengel","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib143","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib144","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma","volume":"131","author":"Kataoka","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib146","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia\u2013lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib147","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib148","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.semdp.2019.12.002","article-title":"Pathology and genetics of anaplastic large cell lymphoma","volume":"37","author":"Leventaki","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib149","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib150","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children\u2019s oncology group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib151","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2023.12.001_bib152","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib153","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","article-title":"Genetic subtyping of breast implant-associated anaplastic large cell lymphoma","volume":"132","author":"Oishi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib154","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/tbj.14205","article-title":"Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway","volume":"27","author":"Quesada","year":"2021","journal-title":"Breast J"},{"key":"10.1016\/j.pathol.2023.12.001_bib155","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/blood.2020005372","article-title":"Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma","volume":"136","author":"Los-de Vries","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib156","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib157","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.001_bib158","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ng.3358","article-title":"Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma","volume":"47","author":"Jiang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib159","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2023.12.001_bib160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/gcc.20245","article-title":"Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma\/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk\/T-cell lymphoma, nasal type","volume":"44","author":"Nakashima","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib161","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib162","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib163","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib164","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","article-title":"Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Polprasert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.001_bib165","first-page":"1058","article-title":"HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma","volume":"135","author":"Sonigo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib166","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3324\/haematol.2020.274506","article-title":"Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma","volume":"107","author":"Bastidas Torres","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib167","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cgh.2005.12.011","article-title":"Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma","volume":"4","author":"Al-Toma","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pathol.2023.12.001_bib168","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.20160894","article-title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","volume":"214","author":"Moffitt","year":"2017","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib169","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1053\/j.gastro.2007.03.036","article-title":"Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes","volume":"132","author":"Deleeuw","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pathol.2023.12.001_bib170","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/modpathol.2015.85","article-title":"Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan","volume":"28","author":"Tomita","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib171","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/gutjnl-2020-322935","article-title":"Oncogenetic landscape of lymphomagenesis in coeliac disease","volume":"71","author":"Cording","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.pathol.2023.12.001_bib172","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-2141.2003.04736.x","article-title":"Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: a study of the Cancer and Leukemia Group B","volume":"124","author":"Wetzler","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib173","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1038\/leu.2009.135","article-title":"PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study","volume":"23","author":"Familiades","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib174","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11790","article-title":"Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukemia","volume":"7","author":"Lilljebj\u00f6rn","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.12.001_bib175","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/gcc.22464","article-title":"ETV6\/RUNX1-like acute lymphoblastic leukaemia: a novel B-cell precursor leukaemia subtype associated with the CD27\/CD44 immunophenotype","volume":"56","author":"Zaliova","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib176","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1182\/bloodadvances.2019001307","article-title":"Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukaemia","volume":"4","author":"Ueno","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.001_bib177","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukaemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib178","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3389\/fonc.2019.01374","article-title":"B-ALL with t(5;14)(q31;q32); IGH-IL3 rearrangement and eosinophilia: a comprehensive analysis of a peculiar IGH-rearranged B-ALL","volume":"9","author":"Fournier","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib179","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","article-title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib180","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.12.001_bib181","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2017.186320","article-title":"Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion","volume":"104","author":"Ohki","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib182","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3324\/haematol.2016.151035","article-title":"ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype","volume":"102","author":"Hirabayashi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib183","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib184","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020009032","article-title":"Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants","volume":"137","author":"Fazio","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib185","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2018-03-842088","article-title":"IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas","volume":"132","author":"Wagener","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib186","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.16578","article-title":"Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group","volume":"190","author":"Au-Yeung","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib187","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","article-title":"A\u00a0recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma","volume":"123","author":"Salaverria","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib188","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1182\/blood-2018-07-864025","article-title":"The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma","volume":"133","author":"Wagener","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib189","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-021-00493-5","article-title":"Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing","volume":"11","author":"Gebauer","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2023.12.001_bib190","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib191","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-021-25405-w","article-title":"Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma","volume":"12","author":"Frontzek","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.12.001_bib192","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3324\/haematol.2020.271957","article-title":"MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma","volume":"106","author":"Ramis-Zaldivar","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib193","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","article-title":"Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases","volume":"38","author":"Morscio","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib194","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/NEN.0000000000000133","article-title":"Immunoglobulin repertoire of primary lymphomas of the central nervous system","volume":"73","author":"Montesinos-Rongen","year":"2014","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.pathol.2023.12.001_bib195","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/bloodadvances.2019000980","article-title":"Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire","volume":"4","author":"Belhouachi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.001_bib196","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib197","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1200\/JCO.2008.16.1455","article-title":"Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course","volume":"26","author":"Cady","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib198","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/bjc.2012.476","article-title":"Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma","volume":"107","author":"Linnebank","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib199","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.pathol.2023.12.001_bib200","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Pham-Ledard","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib201","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.2005.02.0842","article-title":"Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma","volume":"24","author":"Dijkman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib202","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/PAS.0000000000001132","article-title":"High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"42","author":"Schrader","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib203","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.2020007245","article-title":"Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma","volume":"137","author":"Shimada","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib204","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib205","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2023.12.001_bib206","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib207","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jid.2018.02.015","article-title":"Panel sequencing shows recurrent genetic FAS alterations in primary cutaneous marginal zone lymphoma","volume":"138","author":"Maurus","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.pathol.2023.12.001_bib208","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib209","first-page":"470","article-title":"Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection","volume":"90","author":"Traverse-Glehen","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.001_bib210","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/path.5209","article-title":"Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations","volume":"247","author":"Xochelli","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib211","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2141.2008.07176.x","article-title":"Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes","volume":"142","author":"Vega","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.001_bib212","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib213","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.2021012386","article-title":"Genetic and phenotypic attributes of splenic marginal zone lymphoma","volume":"139","author":"Bonfiglio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib214","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib215","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib216","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib217","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib218","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5858\/arpa.2012-0663-OA","article-title":"Fluorescence immunophenotyping and interphase cytogenetics (FICTION) detects BCL6 abnormalities, including gene amplification, in most cases of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"138","author":"Bakhirev","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2023.12.001_bib219","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2005-10-3949","article-title":"Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma","volume":"108","author":"Liso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib220","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/leu.2015.328","article-title":"Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma","volume":"30","author":"Hartmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib221","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.001_bib222","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41375-019-0644-0","article-title":"Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients","volume":"34","author":"Baril\u00e0","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.001_bib223","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood.2020006721","article-title":"Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells","volume":"137","author":"Pastoret","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib224","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.001_bib225","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib226","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.12.001_bib227","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/0008-5472.CAN-07-6398","article-title":"Novel and highly recurrent chromosomal alterations in S\u00e9zary syndrome","volume":"68","author":"Vermeer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2023.12.001_bib228","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41467-018-03987-2","article-title":"Aggressive natural killer-cell leukaemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target","volume":"9","author":"Dufva","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.12.001_bib229","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/PAS.0000000000001518","article-title":"Genomic and immunophenotypic landscape of aggressive NK-cell leukemia","volume":"44","author":"El Hussein","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2023.12.001_bib230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/gcc.10021","article-title":"Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression","volume":"33","author":"Wlodarska","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2023.12.001_bib231","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The genetic basis of hepatosplenic T-cell lymphoma","volume":"7","author":"McKinney","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523003173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523003173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T17:19:37Z","timestamp":1708622377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302523003173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":231,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0031302523003173"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.12.001","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive and prognostic molecular biomarkers in lymphomas","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}